卫材在日本推出新型抗失眠药Dayvigo(lemborexant)

2020-07-07 MedSci原创 MedSci原创

DAYVIGO是一种双重orexin受体拮抗剂,可竞争性结合orexin受体的两种亚型(OX1R和OX2R),从而抑制orexin神经传递调节睡眠觉醒节律。

卫材株式会社宣布在日本推出orexin受体拮抗剂DAYVIGO(lemborexant )片剂,用于治疗失眠症。

DAYVIGO Lemborexant薄膜片说明书

DAYVIGO是一种双重orexin受体拮抗剂,可竞争性结合两种亚型的orexin受体(OX1R和OX2R),从而抑制orexin神经传递调节睡眠觉醒节律。DAYVIGO可通过调节睡眠-苏醒节律来促进和维持睡眠。

日本DAYVIGO的批准是基于两项关键性III期研究(SUNRISE 1和SUNRISE 2)。 

两项结果证实与安慰剂相比,DAYVIGO显着缩短睡眠潜伏期(主要目标)并改善睡眠效率和睡眠后的苏醒(次要目标)。两项研究的分析均表明,DAYVIGO服用一年停药后不会出现戒断反应。

2020年6月,DAYVIGO在美国启动用于治疗失眠的成年患者,其特征是进入睡眠或睡眠维持困难。此外,卫材还提交了一份新药申请,以寻求DAYVIGO在加拿大和澳大利亚的批准。

全世界大约30%的成年人有失眠症状,老年人患病率更高,许多失眠症状会持续数月至数年。

原始出处:

https://www.firstwordpharma.com/node/1737871?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1643062, encodeId=c37e164306233, content=<a href='/topic/show?id=0c3d5e2871' target=_blank style='color:#2F92EE;'>#Dayvigo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5728, encryptionId=0c3d5e2871, topicName=Dayvigo)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1e223091112, createdName=bshuang, createdTime=Sat Mar 27 01:18:05 CST 2021, time=2021-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813414, encodeId=2e3d8134142c, content=lemborexant药物与<a href='/topic/show?id=5d5a44289a3' target=_blank style='color:#2F92EE;'>#失眠#</a>新药daridorexant相比,疗效如何?有必要做一个<a href='/topic/show?id=ea70103822d9' target=_blank style='color:#2F92EE;'>#头对头研究#</a>,或<a href='/topic/show?id=6b3010382368' target=_blank style='color:#2F92EE;'>#network meta分析#</a>了, beContent=null, objectType=article, channel=null, level=null, likeNumber=225, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44289, encryptionId=5d5a44289a3, topicName=失眠), TopicDto(id=103822, encryptionId=ea70103822d9, topicName=头对头研究), TopicDto(id=103823, encryptionId=6b3010382368, topicName=network meta分析)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Aug 26 12:41:57 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946509, encodeId=f44d194650952, content=<a href='/topic/show?id=9b2d4429529' target=_blank style='color:#2F92EE;'>#失眠药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44295, encryptionId=9b2d4429529, topicName=失眠药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3fb2500073, createdName=124987cdm26暂无昵称, createdTime=Sun Jul 12 17:18:05 CST 2020, time=2020-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294555, encodeId=3bf81294555cc, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Jul 09 06:18:05 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447950, encodeId=593d144e95045, content=<a href='/topic/show?id=72233658193' target=_blank style='color:#2F92EE;'>#卫材#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36581, encryptionId=72233658193, topicName=卫材)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de215370353, createdName=yyanpro@23cn.c, createdTime=Thu Jul 09 06:18:05 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602932, encodeId=7ae31602932b2, content=<a href='/topic/show?id=05c41080369' target=_blank style='color:#2F92EE;'>#lemborexant#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10803, encryptionId=05c41080369, topicName=lemborexant)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a51518986254, createdName=ZGMFX30A, createdTime=Thu Jul 09 06:18:05 CST 2020, time=2020-07-09, status=1, ipAttribution=)]
    2021-03-27 bshuang
  2. [GetPortalCommentsPageByObjectIdResponse(id=1643062, encodeId=c37e164306233, content=<a href='/topic/show?id=0c3d5e2871' target=_blank style='color:#2F92EE;'>#Dayvigo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5728, encryptionId=0c3d5e2871, topicName=Dayvigo)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1e223091112, createdName=bshuang, createdTime=Sat Mar 27 01:18:05 CST 2021, time=2021-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813414, encodeId=2e3d8134142c, content=lemborexant药物与<a href='/topic/show?id=5d5a44289a3' target=_blank style='color:#2F92EE;'>#失眠#</a>新药daridorexant相比,疗效如何?有必要做一个<a href='/topic/show?id=ea70103822d9' target=_blank style='color:#2F92EE;'>#头对头研究#</a>,或<a href='/topic/show?id=6b3010382368' target=_blank style='color:#2F92EE;'>#network meta分析#</a>了, beContent=null, objectType=article, channel=null, level=null, likeNumber=225, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44289, encryptionId=5d5a44289a3, topicName=失眠), TopicDto(id=103822, encryptionId=ea70103822d9, topicName=头对头研究), TopicDto(id=103823, encryptionId=6b3010382368, topicName=network meta分析)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Aug 26 12:41:57 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946509, encodeId=f44d194650952, content=<a href='/topic/show?id=9b2d4429529' target=_blank style='color:#2F92EE;'>#失眠药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44295, encryptionId=9b2d4429529, topicName=失眠药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3fb2500073, createdName=124987cdm26暂无昵称, createdTime=Sun Jul 12 17:18:05 CST 2020, time=2020-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294555, encodeId=3bf81294555cc, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Jul 09 06:18:05 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447950, encodeId=593d144e95045, content=<a href='/topic/show?id=72233658193' target=_blank style='color:#2F92EE;'>#卫材#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36581, encryptionId=72233658193, topicName=卫材)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de215370353, createdName=yyanpro@23cn.c, createdTime=Thu Jul 09 06:18:05 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602932, encodeId=7ae31602932b2, content=<a href='/topic/show?id=05c41080369' target=_blank style='color:#2F92EE;'>#lemborexant#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10803, encryptionId=05c41080369, topicName=lemborexant)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a51518986254, createdName=ZGMFX30A, createdTime=Thu Jul 09 06:18:05 CST 2020, time=2020-07-09, status=1, ipAttribution=)]
    2020-08-26 lovetcm

    lemborexant药物与#失眠#新药daridorexant相比,疗效如何?有必要做一个#头对头研究#,或#network meta分析#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1643062, encodeId=c37e164306233, content=<a href='/topic/show?id=0c3d5e2871' target=_blank style='color:#2F92EE;'>#Dayvigo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5728, encryptionId=0c3d5e2871, topicName=Dayvigo)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1e223091112, createdName=bshuang, createdTime=Sat Mar 27 01:18:05 CST 2021, time=2021-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813414, encodeId=2e3d8134142c, content=lemborexant药物与<a href='/topic/show?id=5d5a44289a3' target=_blank style='color:#2F92EE;'>#失眠#</a>新药daridorexant相比,疗效如何?有必要做一个<a href='/topic/show?id=ea70103822d9' target=_blank style='color:#2F92EE;'>#头对头研究#</a>,或<a href='/topic/show?id=6b3010382368' target=_blank style='color:#2F92EE;'>#network meta分析#</a>了, beContent=null, objectType=article, channel=null, level=null, likeNumber=225, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44289, encryptionId=5d5a44289a3, topicName=失眠), TopicDto(id=103822, encryptionId=ea70103822d9, topicName=头对头研究), TopicDto(id=103823, encryptionId=6b3010382368, topicName=network meta分析)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Aug 26 12:41:57 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946509, encodeId=f44d194650952, content=<a href='/topic/show?id=9b2d4429529' target=_blank style='color:#2F92EE;'>#失眠药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44295, encryptionId=9b2d4429529, topicName=失眠药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3fb2500073, createdName=124987cdm26暂无昵称, createdTime=Sun Jul 12 17:18:05 CST 2020, time=2020-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294555, encodeId=3bf81294555cc, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Jul 09 06:18:05 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447950, encodeId=593d144e95045, content=<a href='/topic/show?id=72233658193' target=_blank style='color:#2F92EE;'>#卫材#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36581, encryptionId=72233658193, topicName=卫材)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de215370353, createdName=yyanpro@23cn.c, createdTime=Thu Jul 09 06:18:05 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602932, encodeId=7ae31602932b2, content=<a href='/topic/show?id=05c41080369' target=_blank style='color:#2F92EE;'>#lemborexant#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10803, encryptionId=05c41080369, topicName=lemborexant)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a51518986254, createdName=ZGMFX30A, createdTime=Thu Jul 09 06:18:05 CST 2020, time=2020-07-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1643062, encodeId=c37e164306233, content=<a href='/topic/show?id=0c3d5e2871' target=_blank style='color:#2F92EE;'>#Dayvigo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5728, encryptionId=0c3d5e2871, topicName=Dayvigo)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1e223091112, createdName=bshuang, createdTime=Sat Mar 27 01:18:05 CST 2021, time=2021-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813414, encodeId=2e3d8134142c, content=lemborexant药物与<a href='/topic/show?id=5d5a44289a3' target=_blank style='color:#2F92EE;'>#失眠#</a>新药daridorexant相比,疗效如何?有必要做一个<a href='/topic/show?id=ea70103822d9' target=_blank style='color:#2F92EE;'>#头对头研究#</a>,或<a href='/topic/show?id=6b3010382368' target=_blank style='color:#2F92EE;'>#network meta分析#</a>了, beContent=null, objectType=article, channel=null, level=null, likeNumber=225, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44289, encryptionId=5d5a44289a3, topicName=失眠), TopicDto(id=103822, encryptionId=ea70103822d9, topicName=头对头研究), TopicDto(id=103823, encryptionId=6b3010382368, topicName=network meta分析)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Aug 26 12:41:57 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946509, encodeId=f44d194650952, content=<a href='/topic/show?id=9b2d4429529' target=_blank style='color:#2F92EE;'>#失眠药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44295, encryptionId=9b2d4429529, topicName=失眠药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3fb2500073, createdName=124987cdm26暂无昵称, createdTime=Sun Jul 12 17:18:05 CST 2020, time=2020-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294555, encodeId=3bf81294555cc, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Jul 09 06:18:05 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447950, encodeId=593d144e95045, content=<a href='/topic/show?id=72233658193' target=_blank style='color:#2F92EE;'>#卫材#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36581, encryptionId=72233658193, topicName=卫材)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de215370353, createdName=yyanpro@23cn.c, createdTime=Thu Jul 09 06:18:05 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602932, encodeId=7ae31602932b2, content=<a href='/topic/show?id=05c41080369' target=_blank style='color:#2F92EE;'>#lemborexant#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10803, encryptionId=05c41080369, topicName=lemborexant)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a51518986254, createdName=ZGMFX30A, createdTime=Thu Jul 09 06:18:05 CST 2020, time=2020-07-09, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1643062, encodeId=c37e164306233, content=<a href='/topic/show?id=0c3d5e2871' target=_blank style='color:#2F92EE;'>#Dayvigo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5728, encryptionId=0c3d5e2871, topicName=Dayvigo)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1e223091112, createdName=bshuang, createdTime=Sat Mar 27 01:18:05 CST 2021, time=2021-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813414, encodeId=2e3d8134142c, content=lemborexant药物与<a href='/topic/show?id=5d5a44289a3' target=_blank style='color:#2F92EE;'>#失眠#</a>新药daridorexant相比,疗效如何?有必要做一个<a href='/topic/show?id=ea70103822d9' target=_blank style='color:#2F92EE;'>#头对头研究#</a>,或<a href='/topic/show?id=6b3010382368' target=_blank style='color:#2F92EE;'>#network meta分析#</a>了, beContent=null, objectType=article, channel=null, level=null, likeNumber=225, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44289, encryptionId=5d5a44289a3, topicName=失眠), TopicDto(id=103822, encryptionId=ea70103822d9, topicName=头对头研究), TopicDto(id=103823, encryptionId=6b3010382368, topicName=network meta分析)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Aug 26 12:41:57 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946509, encodeId=f44d194650952, content=<a href='/topic/show?id=9b2d4429529' target=_blank style='color:#2F92EE;'>#失眠药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44295, encryptionId=9b2d4429529, topicName=失眠药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3fb2500073, createdName=124987cdm26暂无昵称, createdTime=Sun Jul 12 17:18:05 CST 2020, time=2020-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294555, encodeId=3bf81294555cc, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Jul 09 06:18:05 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447950, encodeId=593d144e95045, content=<a href='/topic/show?id=72233658193' target=_blank style='color:#2F92EE;'>#卫材#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36581, encryptionId=72233658193, topicName=卫材)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de215370353, createdName=yyanpro@23cn.c, createdTime=Thu Jul 09 06:18:05 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602932, encodeId=7ae31602932b2, content=<a href='/topic/show?id=05c41080369' target=_blank style='color:#2F92EE;'>#lemborexant#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10803, encryptionId=05c41080369, topicName=lemborexant)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a51518986254, createdName=ZGMFX30A, createdTime=Thu Jul 09 06:18:05 CST 2020, time=2020-07-09, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1643062, encodeId=c37e164306233, content=<a href='/topic/show?id=0c3d5e2871' target=_blank style='color:#2F92EE;'>#Dayvigo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5728, encryptionId=0c3d5e2871, topicName=Dayvigo)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1e223091112, createdName=bshuang, createdTime=Sat Mar 27 01:18:05 CST 2021, time=2021-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813414, encodeId=2e3d8134142c, content=lemborexant药物与<a href='/topic/show?id=5d5a44289a3' target=_blank style='color:#2F92EE;'>#失眠#</a>新药daridorexant相比,疗效如何?有必要做一个<a href='/topic/show?id=ea70103822d9' target=_blank style='color:#2F92EE;'>#头对头研究#</a>,或<a href='/topic/show?id=6b3010382368' target=_blank style='color:#2F92EE;'>#network meta分析#</a>了, beContent=null, objectType=article, channel=null, level=null, likeNumber=225, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44289, encryptionId=5d5a44289a3, topicName=失眠), TopicDto(id=103822, encryptionId=ea70103822d9, topicName=头对头研究), TopicDto(id=103823, encryptionId=6b3010382368, topicName=network meta分析)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Aug 26 12:41:57 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946509, encodeId=f44d194650952, content=<a href='/topic/show?id=9b2d4429529' target=_blank style='color:#2F92EE;'>#失眠药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44295, encryptionId=9b2d4429529, topicName=失眠药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3fb2500073, createdName=124987cdm26暂无昵称, createdTime=Sun Jul 12 17:18:05 CST 2020, time=2020-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294555, encodeId=3bf81294555cc, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Jul 09 06:18:05 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447950, encodeId=593d144e95045, content=<a href='/topic/show?id=72233658193' target=_blank style='color:#2F92EE;'>#卫材#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36581, encryptionId=72233658193, topicName=卫材)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de215370353, createdName=yyanpro@23cn.c, createdTime=Thu Jul 09 06:18:05 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602932, encodeId=7ae31602932b2, content=<a href='/topic/show?id=05c41080369' target=_blank style='color:#2F92EE;'>#lemborexant#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10803, encryptionId=05c41080369, topicName=lemborexant)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a51518986254, createdName=ZGMFX30A, createdTime=Thu Jul 09 06:18:05 CST 2020, time=2020-07-09, status=1, ipAttribution=)]

相关资讯

Mayo Clin Proc:药物处方中的引起失眠症的信息是否与随机证据一致?

很多药物会引起失眠症,但处方信息是否与已有证据一致呢?2017年1月,发表在《Mayo Clin Proc》的一项研究显示,目前相关的处方信息只有部分与已有的随机证据一致。

Maturitas:中年女性运动对睡眠质量和失眠症的影响

目的:评估系统性运动(programmedexercise, PE)对中年女性(middle-agedwomen, MAW)睡眠质量和失眠症的影响。

JAMA Network Open:DAYVIGO(lemborexant)治疗失眠症的关键III期研究

卫材制药近日宣布,JAMA Network Open发布了SUNRISE 1研究的结果,在失眠症患者中比较了DAYVIGO(左硼苯甲酸酯)和安慰剂的有效性和安全性。结果显示,与安慰剂相比,DAYVIGO治疗显著改善了睡眠发作和睡眠维持。

中国失眠症诊断和治疗指南

2015年10月,中国睡眠研究会在北京召开会议,邀请来自国内多家大型三甲医院、涵盖与睡眠医学相关的多个科室(包括精神科、心理科、神经内科、呼吸科、儿科、中医科等)的睡眠医学专家成立指南制定专家委员会,以编制适合国情的失眠症诊断和治疗指南专家组经过反复和充分论证,结合现有的临床经验和国内外最新研究成果,特别是循证医学方面的证据,历时1年时间完成了指南的撰写。本指南旨在为临床医师、护理人员、药剂师和心

失眠症治疗迎来曙光:FDA已批准卫材的Dayvigo

卫材公司近日宣布,FDA已经批准Dayvigo(lemborexant)用于治疗以睡眠发作和/或睡眠维持困难为特征的成人失眠症。该公司指出,Dayvigo(lemborexant)将于2020年4月上旬上市。

2016失眠症中医临床实践指南(WHO/WPO)发布

 20 世纪90年代以来,临床睡眠医学得到迅速发展,引进、运用现代睡眠医学的理论与技术,结合中医药学的特点,开展中医睡眠医学理论与临床研究,在整理和继承中医药传统理论的同时,发展了现代中医睡眠医学,促进了中医药在睡眠医学研究领域的进步。 失眠是一种常见的症状,绝大多数人都有偶尔失眠的经历,但这并不代表疾病状态。失眠症是临床常见的睡眠障碍之一,它影响大众身心健康、脑思维、记忆、创